Dachaigh › Galar Crohn › Connecticut
Sgrùdaidhean clionaigeach Galar Crohn ann an Connecticut
Tha 14 sgrùdaidhean airson Galar Crohn a’ lorg phàirtichean aig làraichean ann an Connecticut.
Bailtean ann an Connecticut
Teacsa sgrùdaidh oifigeil (Beurla)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT03816345Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Connecticut Clinical Research Institute ( Site 0297), Bristol
A’ fastadhÌre 3
Gach aois · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Yale University School of Medicine-Digestive Disease ( Site 5019), New Haven
A’ fastadhÌre 3
Aoisean 16 gu 80 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06430801Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Danbury Hospital, Western Connecticut Health Network /ID# 265556, Danbury
- Yale University School of Medicine /ID# 266786, New Haven
A’ fastadhÌre 2
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Medical Research Center of Connecticut, Hamden
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT07499232An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Yale University Digestive Disease-Site Number: 8400108, New Haven
A’ fastadhÌre 3
Aoisean 16 gu 80 · Gach gnè · Air ùrachadh 23 Sult 2026 · NCT07184931A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Connecticut Children's Medical Center, Hartford
A’ fastadhÌre 3
Aoisean 2 gu 19 · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT04844606A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Medical Research Center of Connecticut, LLC, Hamden
A’ fastadhÌre 4
Aoisean 18 gu 70 · Gach gnè · Air ùrachadh 9 Sult 2026 · NCT06045754A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
A’ fastadhÌre 3
Aoisean 2 gu 17 · Gach gnè · Air ùrachadh 24 Lùna 2026 · NCT05509777Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Yale University, New Haven
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 7 Lùna 2026 · NCT05230173Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Yale University School of Medicine, New Haven
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Lùna 2026 · NCT07237516Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
- Connecticut Children's Medical Center, Hartford
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 10 gu 21 · Gach gnè · Air ùrachadh 16 Iuch 2026 · NCT07224113Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Connecticut Children's Medical Center - Hartford /ID# 262256, Hartford
A’ fastadhÌre 3
Aoisean 2 gu 17 · Gach gnè · Air ùrachadh 24 Ògmh 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
A’ fastadhÌre 4
Aoisean 6 gu 17 · Gach gnè · Air ùrachadh 27 Cèit 2026 · NCT05781152Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.